Accession Number : ADA288960
Title : Neuropharmacological Characterization of Botulinum Neurotoxin.
Descriptive Note : Final rept. 30 Mar 90-31 Dec 93,
Corporate Author : JEFFERSON MEDICAL COLL PHILADELPHIA PA
Personal Author(s) : Simpson, Lance L.
PDF Url : ADA288960
Report Date : 22 SEP 1994
Pagination or Media Count : 76
Abstract : Studies have been done in three general areas: (i) study of the mechanism of action of botulinum neurotoxin, (ii) identification of drugs that antagonize botulinum neurotoxin action, and (iii) extension of basic science studies on toxin action to the human nervous system. The two principal tissue preparations used were the mouse phrenic nerve-hemidiaphragm and the human pyramidalis muscle. The major findings were: (i) stimulation of transglutaminase activity is not likely to be relevant to clostridial toxin action, (ii) zinc chelators, such as TPEN, are intracellular antagonists of all clostridial neurotoxins, (iii) inihibitors of vascuolar adenosine triphosphatase, such as bafilomycin, antagonize all clostridial neurotoxins but not phospholipase A2 neurotoxins, and (iv) human neuromuscular junctions are sensitive to all botulinum serotypes associated with natural poisoning (e.g. , A, B, and E), and they are also sensitive to one serotype that is not typically associated with natural poisoning (e.g., C).
Descriptors : *NERVOUS SYSTEM, *TOXINS AND ANTITOXINS, *BACTERIAL TOXINS, *CHOLINERGIC NERVES, TISSUES(BIOLOGY), STIMULATION(GENERAL), HUMANS, SENSITIVITY, CLOSTRIDIUM, IDENTIFICATION, POISONING, MUSCLES, DRUGS, JUNCTIONS, CELLS(BIOLOGY), SEROLOGY, ANTIGENS, NERVES, CNS DEPRESSANTS, PHARMACOLOGICAL ANTAGONISTS, CLOSTRIDIUM BOTULINUM.
Subject Categories : Anatomy and Physiology
Distribution Statement : APPROVED FOR PUBLIC RELEASE